TY - JOUR
T1 - Immuno-Oncology biomarkers 2010 and beyond
T2 - Perspectives from the iSBTc/SITC biomarker task force
AU - Butterfield, Lisa H.
AU - Disis, Mary L.
AU - Khleif, Samir N.
AU - Balwit, James M.
AU - Marincola, Francesco M.
PY - 2010/12/7
Y1 - 2010/12/7
N2 - The International Society for Biological Therapy of Cancer (iSBTc, recently renamed the Society for Immunotherapy of Cancer, SITC) hosted a one-day symposium at the National Institutes of Health on September 30, 2010 to address development and application of biomarkers in cancer immunotherapy. The symposium, titled Immuno-Oncology Biomarkers 2010 and Beyond: Perspectives from the iSBTc/SITC Biomarker Task Force, gathered approximately 230 investigators equally from academia, industry and governmental/regulatory agencies from around the globe for panel discussions and presentations on the following topics: 1) immunologic monitoring: standardization and validation of assays; 2) correlation of immunity to biologic activity, clinical response and potency assays; 3) novel methodologies for assessing the immune landscape: clinical utility of novel technologies; and 4) recommendations on incorporation of biomarkers into the clinical arena. The presentations are summarized in this report; additional program information and slides are available online at the iSBTc/SITC website.
AB - The International Society for Biological Therapy of Cancer (iSBTc, recently renamed the Society for Immunotherapy of Cancer, SITC) hosted a one-day symposium at the National Institutes of Health on September 30, 2010 to address development and application of biomarkers in cancer immunotherapy. The symposium, titled Immuno-Oncology Biomarkers 2010 and Beyond: Perspectives from the iSBTc/SITC Biomarker Task Force, gathered approximately 230 investigators equally from academia, industry and governmental/regulatory agencies from around the globe for panel discussions and presentations on the following topics: 1) immunologic monitoring: standardization and validation of assays; 2) correlation of immunity to biologic activity, clinical response and potency assays; 3) novel methodologies for assessing the immune landscape: clinical utility of novel technologies; and 4) recommendations on incorporation of biomarkers into the clinical arena. The presentations are summarized in this report; additional program information and slides are available online at the iSBTc/SITC website.
UR - http://www.scopus.com/inward/record.url?scp=78649750575&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=78649750575&partnerID=8YFLogxK
U2 - 10.1186/1479-5876-8-130
DO - 10.1186/1479-5876-8-130
M3 - Comment/debate
C2 - 21138581
AN - SCOPUS:78649750575
SN - 1479-5876
VL - 8
JO - Journal of Translational Medicine
JF - Journal of Translational Medicine
M1 - 130
ER -
